Evaluation of helicobacter pylori eradication therapy with serum myeloperoxidase levels

Özet

Helicobacter pylori (H. pylori) is associated with chronic gastritis, peptic ulcers, and gastric adenocarcinomas. H. pylori-infected patients produce reactive oxygen species (ROS) in gastric mucosa. Production of ROS induces the myeloperoxidase (MPO) activity. This study aims the determination of the relationship between MPO level and H. pylori infection and eradication therapy. One hundred seven (107) patients were enrolled in the study. H. pylori were detected by histopathological examination of the specimens. The patients were divided into two groups: Group 1 (H. pylori-negative), Group 2 (H. pylori-positive). The tissue MPO activity and serum MPO levels of these two groups were compared. Patients with H. pylori infection received eradication therapy. Post-treatment serum MPO levels were also compared. Histopathological examination revealed that 28(26.2%) patients were H. pylori-negative (Group 1), whereas 79(73.8%) patients were H. pylori-positive (Group 2). Tissue MPO activity of the groups was compared, and a significant difference was found between two groups, 0.5(1) and 2(1), respectively (p<0.001). There was no significant difference between the groups in terms of serum MPO levels 2.19(1.91) ng/mL and 2.69(2.45) ng/mL, respectively (P=0.266). There was a significant difference between pre-treatment and post-treatment serum MPO levels after eradication therapy 2.69(2.45) and 1.26(2.36), respectively (p=0.002). Consequently, MPO levels may be determinant in monitoring the effectiveness of H. pylori eradication therapy